Rogier Versteeg

29.2k total citations · 2 hit papers
174 papers, 10.8k citations indexed

About

Rogier Versteeg is a scholar working on Neurology, Molecular Biology and Cancer Research. According to data from OpenAlex, Rogier Versteeg has authored 174 papers receiving a total of 10.8k indexed citations (citations by other indexed papers that have themselves been cited), including 115 papers in Neurology, 108 papers in Molecular Biology and 51 papers in Cancer Research. Recurrent topics in Rogier Versteeg's work include Neuroblastoma Research and Treatments (115 papers), Cancer, Hypoxia, and Metabolism (41 papers) and Microtubule and mitosis dynamics (20 papers). Rogier Versteeg is often cited by papers focused on Neuroblastoma Research and Treatments (115 papers), Cancer, Hypoxia, and Metabolism (41 papers) and Microtubule and mitosis dynamics (20 papers). Rogier Versteeg collaborates with scholars based in Netherlands, United States and Germany. Rogier Versteeg's co-authors include Jan Köster, Huib N. Caron, Peter van Sluis, Jan J. Molenaar, Linda J. Valentijn, P.A. Voûte, Max M. van Noesel, Geneviève Laureys, Peter I. Schrier and Kathy Boon and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Rogier Versteeg

172 papers receiving 10.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Human Transcriptome Map: Clustering of Highly Expressed Genes in Chromosomal Domains

2001 571 citations Huib N. Caron, Frank Baas et al. profile →
The Lgr5 intestinal stem cell signature: robust expression of proposed quiescent ‘+4’ cell markers

2012 562 citations Richard Volckmann, Jan Köster et al. profile →

Peers

Countries citing papers authored by Rogier Versteeg

Since Specialization

Citations

This map shows the geographic impact of Rogier Versteeg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rogier Versteeg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rogier Versteeg more than expected).

Fields of papers citing papers by Rogier Versteeg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rogier Versteeg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rogier Versteeg. The network helps show where Rogier Versteeg may publish in the future.

Co-authorship network of co-authors of Rogier Versteeg

This figure shows the co-authorship network connecting the top 25 collaborators of Rogier Versteeg. A scholar is included among the top collaborators of Rogier Versteeg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rogier Versteeg. Rogier Versteeg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma 2023 ·Frontiers in Oncology ·Thomas F. Eleveld, (unknown), Linda Schild, (unknown), Lindy K. Alles, Marli E. Ebus, (unknown), Harm van Tinteren, Huib N. Caron, Jan Köster, Max M. van Noesel, Godelieve A.M. Tytgat, Selma Eising, Rogier Versteeg, M. Emmy M. Dolman, Jan J. Molenaar	6
2	FOXO3A‐short is a novel regulator of non‐oxidative glucose metabolism associated with human longevity 2023 ·Aging Cell ·Evan E. Santo, Rasmus Ribel‐Madsen, Peter Stroeken, Vincent C. J. de Boer, Ninna S. Hansen, (unknown), Allan Vaag, Rogier Versteeg, Jihye Paik, Ellen M. Westerhout	8
3	DHODH is an independent prognostic marker and potent therapeutic target in neuroblastoma 2022 ·JCI Insight ·Thale Kristin Olsen, Cecilia Dyberg, (unknown), (unknown), Jelena Milosevic, Jane Ding, Jörg Otte, (unknown), Ida Hed Myrberg, Ellen M. Westerhout, Jan Köster, Rogier Versteeg, Han‐Fei Ding, Per Kogner, John Inge Johnsen, David B. Sykes, Ninib Baryawno	21
4	Defects in 8-oxo-guanine repair pathway cause high frequency of C > A substitutions in neuroblastoma 2021 ·Proceedings of the National Academy of Sciences ·Marlinde L. van den Boogaard, Rurika Oka, (unknown), Linda Schild, Marli E. Ebus, (unknown), Danny A. Zwijnenburg, Piet Molenaar, (unknown), M. Emmy M. Dolman, Anke H. W. Essing, (unknown), Thomas Helleday, Jarno Drost, Ruben van Boxtel, Rogier Versteeg, Jan Köster, Jan J. Molenaar	17
5	A NOTCH feed-forward loop drives reprogramming from adrenergic to mesenchymal state in neuroblastoma 2019 ·Nature Communications ·Tim van Groningen, Nurdan Akogul, Ellen M. Westerhout, Alvin Chan, Nancy E. Hasselt, Danny A. Zwijnenburg, Marloes E.C. Broekmans, Peter Stroeken, Franciska Haneveld, Gerrit K. Hooijer, C. Dilara Savci‐Heijink, Arjan Lakeman, Richard Volckmann, Peter van Sluis, Linda J. Valentijn, Jan Köster, Rogier Versteeg, Johan van Nes	95
6	RAS–MAPK Pathway-Driven Tumor Progression Is Associated with Loss of CIC and Other Genomic Aberrations in Neuroblastoma 2018 ·Cancer Research ·Thomas F. Eleveld, Linda Schild, Jan Köster, Danny A. Zwijnenburg, Lindy K. Alles, Marli E. Ebus, Richard Volckmann, (unknown), Peter van Sluis, Rogier Versteeg, Jan J. Molenaar	40
7	Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma 2015 ·Clinical Cancer Research ·M. Emmy M. Dolman, Evon Poon, Marli E. Ebus, (unknown), Carel J.M. van Noesel, Yann Jamin, Albert Hallsworth, Simon P. Robinson, Kevin Petrie, Rolf W. Sparidans, Robbert J. Kok, Rogier Versteeg, Huib N. Caron, Louis Chesler, Jan J. Molenaar	47
8	Selection of Personalized Patient Therapy through the Use of Knowledge-Based Computational Models That Identify Tumor-Driving Signal Transduction Pathways 2014 ·Cancer Research ·Wim Verhaegh, (unknown), Márcia A. Inda, Pantelis Hatzis, Rogier Versteeg, Marcel Smid, John W.M. Martens, John A. Foekens, (unknown), Hans Clevers, Anja van de Stolpe	62
9	FOXO3a Is a Major Target of Inactivation by PI3K/AKT Signaling in Aggressive Neuroblastoma 2013 ·Cancer Research ·Evan E. Santo, Peter Stroeken, Peter van Sluis, Jan Köster, Rogier Versteeg, Ellen M. Westerhout	117
10	A NOTCH3 Transcriptional Module Induces Cell Motility in Neuroblastoma 2013 ·Clinical Cancer Research ·Johan van Nes, Alvin Chan, Tim van Groningen, Peter van Sluis, Jan Köster, Rogier Versteeg	33
11	Histone Chaperone CHAF1A Inhibits Differentiation and Promotes Aggressive Neuroblastoma 2013 ·Cancer Research ·Eveline Barbieri, Katleen De Preter, Mario Capasso, Zaowen Chen, (unknown), Gian Paolo Tonini, Steve Lefever, John Hicks, Rogier Versteeg, Andrea Pession, Frank Speleman, Eugene S. Kim, Jason M. Shohet	44
12	Mutations in the Ras–Raf Axis Underlie the Prognostic Value of CD133 in Colorectal Cancer 2012 ·Clinical Cancer Research ·Kristel Kemper, Miranda Versloot, Katherine Cameron, Selçuk Çolak, Felipe de Sousa e Melo, Joan H. de Jong, (unknown), Louis Vermeulen, Rogier Versteeg, Jan Köster, Jan Paul Medema	76
13	Methylated RASSF1a Is the First Specific DNA Marker for Minimal Residual Disease Testing in Neuroblastoma 2011 ·Clinical Cancer Research ·Janine Stutterheim, (unknown), (unknown), Rogier Versteeg, Huib N. Caron, Godelieve A.M. Tytgat, C. Ellen van der Schoot	28
14	Regulation of Cell Cycle Genes and Induction of Senescence by Overexpression of OTX2 in Medulloblastoma Cell Lines 2010 ·Molecular Cancer Research ·Jens Bunt, (unknown), Nancy E. Hasselt, Danny A. Zwijnenburg, Jan Köster, Rogier Versteeg, Marcel Kool	36
15	Silencing of SPRY1 Triggers Complete Regression of Rhabdomyosarcoma Tumors Carrying a Mutated RAS Gene 2010 ·Cancer Research ·Gerben Schaaf, Mohamed Hamdi, Danny A. Zwijnenburg, Arjan Lakeman, Dirk Geerts, Rogier Versteeg, Marcel Kool	55
16	Lysine-Specific Demethylase 1 Is Strongly Expressed in Poorly Differentiated Neuroblastoma: Implications for Therapy 2009 ·Cancer Research ·Johannes H. Schulte, Soyoung Lim, Alexander Schramm, Nicolaus Friedrichs, Jan Köster, Rogier Versteeg, Ingrid Øra, Kristian W. Pajtler, Ludger Klein‐Hitpaß, Steffi Kuhfittig-Kulle, Eric Metzger, Roland Schüle, Angelika Eggert, Reinhard Buettner, Jutta Kirfel	369
17	Molecular Risk Stratification of Medulloblastoma Patients Based on Immunohistochemical Analysis of MYC, LDHB, and CCNB1 Expression 2008 ·Clinical Cancer Research ·(unknown), Nancy E. Hasselt, Dirk Troost, Huib N. Caron, Mara Popović, Lorna Zadravec Zaletel, Wiesława Grajkowska, Marta Perek‐Polnik, Maria‐Chiara Osterheld, David W. Ellison, Frank Baas, Rogier Versteeg, Marcel Kool	41
18	Expression of Prenylated Rab Acceptor 1 Domain Family, Member 2 (PRAF2) in Neuroblastoma: Correlation with Clinical Features, Cellular Localization, and Cerulenin-Mediated Apoptosis Regulation 2007 ·Clinical Cancer Research ·Dirk Geerts, Christopher J. Wallick, (unknown), Jan Köster, Rogier Versteeg, (unknown), André S. Bachmann	22
19	The MSX1 homeobox transcription factor is a downstream target of PHOX2B and activates the Delta–Notch pathway in neuroblastoma 2007 ·Experimental Cell Research ·Ingrid Revet, (unknown), Alvin Chan, Jan Köster, Richard Volckmann, Peter van Sluis, Ingrid Øra, Rogier Versteeg, Dirk Geerts	65
20	A constitutional balanced 1;17 neuroblastoma translocation 1997 ·European Journal of Cancer ·(unknown), Peter van Sluis, Jan de Kraker, J.P.M. Bökkerink, Maarten Egeler, Geneviève Laureys, Voûte Pa, R Släter, A. Westerveld, Rogier Versteeg	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact